Comparisons of noncoronary sinus pivot implantation (NCPI) and conventional method for transcatheter aortic valve replacement with self‐expanding valve in pure aortic regurgitation (PAR)
Catheterization and Cardiovascular Interventions · 2024-06 · 103 (7) · 1093-1100
DOI: 10.1002/ccd.31064 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024-05. Verfasst von Lifan Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University Minhang Meilong, Shanghai, China. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Insufficiency, Heart Valve Prosthesis, Aortic Valve. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: National Key R&D Program of China.
Abstract (Originalsprache)
Background
As compared to treatment of aortic stenosis (AS), transcatheter aortic valve replacement (TAVR) using the commercially available valves to treat pure aortic regurgitation (PAR) has a lower device success rate and higher complication rates.
Aims
The study compared the acute results between TAVR using a novel noncoronary sinus pivot implantation (NCPI) method and that using the conventional method, aiming to explore a more optimized and effective operation method for TAVR in PAR.
Methods
PAR patients who underwent TAVR with self‐expanding valves in our center from September 2021 to September 2023 were enrolled were divided into the NCPI (group A, N = 16) and conventional method (group B, N = 39) groups. We analyzed the pre‐operative evaluation parameters and procedural and postoperative data of the two subgroups.
Results
The total patients’ mean age was 71.2 ± 8.7 years and most were male (61.8%), with a mean Society of Thoracic Surgeons score of 3.4 ± 1.9%. The device success rate of groups A and B was 100% and 71.8%, respectively. In group B, 48.7% had major adverse cardiac events (MACE); 46.2% patients had permanent pacemaker implantation or valve in valve implantation. None had MACE in group A. The noncoronary sinus implantation depth in NCPI was −1.1 + 1.0 and 4.2 + 3.7 mm in groups A and B ( p < 0.001), respectively.
Conclusions
TAVR with a self‐expanding valve using the NCPI method had a higher procedure success rate and dramatically low complications than that using the conventional method in PAR patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University Minhang Meilong, Shanghai, China.
- National Clinical Research Center for Interventional Medicine, Shanghai, China.
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Daxin Zhou, Wenzhi Pan, Junbo Ge
Förderung
- National Key R&D Program of China
Zitieren
APA
Yang, L., Chen, S., Zhang, X., Zhang, Y., Zhou, D., Pan, W., & Ge, J. (2024). Comparisons of noncoronary sinus pivot implantation (NCPI) and conventional method for transcatheter aortic valve replacement with self‐expanding valve in pure aortic regurgitation (PAR). Catheterization and Cardiovascular Interventions, 103(7), 1093-1100. https://doi.org/10.1002/ccd.31064
Vancouver
Yang L, Chen S, Zhang X, Zhang Y, Zhou D, Pan W, et al. Comparisons of noncoronary sinus pivot implantation (NCPI) and conventional method for transcatheter aortic valve replacement with self‐expanding valve in pure aortic regurgitation (PAR). Catheterization and Cardiovascular Interventions. 2024;103(7):1093-1100. doi:10.1002/ccd.31064
BibTeX
@article{Yang2024,
author = {Yang, Lifan and Chen, Shasha and Zhang, Xiaochun and Zhang, Yuan and Zhou, Daxin and Pan, Wenzhi and Ge, Junbo},
title = {Comparisons of noncoronary sinus pivot implantation (NCPI) and conventional method for transcatheter aortic valve replacement with self‐expanding valve in pure aortic regurgitation (PAR)},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
volume = {103},
number = {7},
pages = {1093--1100},
doi = {10.1002/ccd.31064}
}
EUVIMED